|Bid||158.30 x 800|
|Ask||159.29 x 800|
|Day's Range||156.75 - 158.64|
|52 Week Range||114.27 - 197.00|
|Beta (3Y Monthly)||1.95|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||2.96 (1.88%)|
|1y Target Est||N/A|
- Q2 2019 GAAP Net Revenues of $4.09 Billion - - Q2 2019 GAAP Loss Per Share of $5.37 ; Non-GAAP Performance Net Income Per Share of $4.38 - - Q2 2019 GAAP Operating Loss of $1.26 Billion ; Non-GAAP Operating ...
DUBLIN , Aug. 2, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release second quarter 2019 financial results on Tuesday, August 6, 2019 , prior to the open of U.S. financial markets. ...
DUBLIN, July 29, 2019 /PRNewswire/ -- Allergan plc (AGN) announced today a partnership with actress, musician and producer Ashley Tisdale, bringing awareness to the digital-first 'Women Who Know' campaign that inspires women who are writing their own futures to take charge of their decisions when it comes to reproductive health and contraceptive options. Allergan, the maker of the #1-prescribed branded birth control pill by OB/GYNs,1 Lo Loestrin®Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets), has chosen Tisdale to represent the 'Woman Who Knows,' a confident, savvy and empowered woman looking to be proactive about her individual journey with pregnancy prevention.
Allergan plc (AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced the Brilliance Phase 1/2 clinical trial of AGN-151587 (EDIT-101) is open for patient enrollment. AGN-151587 is an experimental medicine under development for the treatment of Leber congenital amaurosis 10 (LCA10), an inherited form of blindness caused by mutations in the CEP290 gene. The clinical trial will be the world’s first in vivo study of a CRISPR-based genome editing medicine, where the editing takes place inside the human body.
Global Action Follows Notification of Updated Safety Information from the U.S. Food and Drug Administration (FDA) -- FDA Does Not Recommend Removal or Replacement of Textured Breast Implants in Asymptomatic ...
- Dividend to be Paid on September 13, 2019 - - Record Date of August 13, 2019 - DUBLIN , July 19, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its Board of Directors has declared ...
THOUSAND OAKS, Calif., July 18, 2019 /PRNewswire/ -- Amgen (AMGN) and Allergan plc (AGN) today announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), are now available in the United States (U.S.).
A federal judge yesterday greenlighted a class-action lawsuit against Allergan subsidiaries Warner Chilcott and Watson for overcharging direct purchasers for Loestrin 24, Minastrin and generic equivalents, according to Hagens Berman. According to the order unsealed July 16, 2019, by Chief Judge William E. Smith of the District of Rhode Island, damages to the class are on the order of $625.2 million – $1.9 billion after automatic trebling under antitrust rules. Trial in the class-action lawsuit is set for January 6, 2020, in Providence, Rhode Island.
DUBLIN, July 17, 2019 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for Bimatoprost Sustained-Release (SR). Bimatoprost SR if approved would be the first-in-class sustained-release, biodegradable implant for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.
NEW YORK, July 12, 2019 -- Halper Sadeh LLP, a global investor rights law firm, is investigating the following companies: Del Frisco’s Restaurant Group, Inc. (NASDAQ: DFRG)The.
-- Allergan MIND™, Allergan's migraine franchise, showcases data highlighting BOTOX® (onabotulinumtoxinA) for Chronic Migraine, and two investigational products: ubrogepant and atogepant -- -- Pivotal ...
NEW YORK, July 03, 2019 -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Oritani Financial Corp.,.
NEW YORK, June 26, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Allergan plc (NYSE: AGN) on behalf of Allergan.
NEW YORK, June 26, 2019 -- Halper Sadeh LLP, a global investor rights law firm, is investigating Allergan plc (NYSE: AGN), Del Frisco’s Restaurant Group, Inc. (NASDAQ: DFRG),.
NEW YORK , June 25, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Allergan Plc ("Allergan" ...
NEW YORK, June 25, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Allergan plc (“Allergan” or the.
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Allergan plc (AGN) to AbbVie Inc. (“AbbVie”) is fair to Allergan shareholders. On behalf of Allergan shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. If you are an Allergan shareholder and would like to discuss your legal rights and options, please visit Allergan Merger or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or email@example.com or firstname.lastname@example.org.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION ...
DUBLIN, June 24, 2019 /PRNewswire/ -- Allergan plc (AGN) today announced CoolTone device received FDA clearance for improvement of abdominal tone, strengthening of the abdominal muscles, and development for firmer abdomen. "As the global leader in medical aesthetics and body contouring, Allergan invests in the ongoing innovation and advancement of safe and effective non-surgical aesthetic solutions," said Brad Hauser, Vice President, R&D and General Manager, Body Contouring, Allergan.
DUBLIN, June 21, 2019 /PRNewswire/ -- Allergan plc (AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental biologics application (sBLA) for BOTOX® for the treatment of pediatric patients (2 to 17 years of age) with upper limb spasticity. BOTOX® was granted a six-month Priority Review by the FDA, which is typically granted to therapies that if approved, could offer significant improvements in safety and effectiveness when compared to current standard of care.
Ironwood Pharmaceuticals, Inc. (IRWD) and Allergan plc (AGN) today announced positive topline data from a Phase IIIb clinical trial evaluating LINZESS (linaclotide) 290 mcg on multiple abdominal symptoms in adult patients with IBS-C. The trial met its primary multi-component endpoint and demonstrated that linaclotide improved the overall abdominal symptoms of bloating, pain and discomfort in adult IBS-C patients compared to placebo. The trial also met both secondary endpoints.
THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (AMGN) and Allergan plc (AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
- New Indication Makes VRAYLAR First and Only Dopamine and Serotonin Partial Agonist to Treat the Full Spectrum of Bipolar I Symptoms in Manic, Mixed, and Depressive Episodes - DUBLIN and BUDAPEST, Hungary ...